Legal & General Group Plc Lowers Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Legal & General Group Plc decreased its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 34.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,250,262 shares of the company's stock after selling 1,740,342 shares during the quarter. Legal & General Group Plc owned 0.29% of Teva Pharmaceutical Industries worth $71,636,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of TEVA. FMR LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 30.7% in the fourth quarter. FMR LLC now owns 81,983,231 shares of the company's stock valued at $1,806,910,000 after acquiring an additional 19,242,468 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd lifted its stake in shares of Teva Pharmaceutical Industries by 12.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock valued at $859,935,000 after purchasing an additional 4,418,961 shares during the last quarter. Lingotto Investment Management LLP boosted its holdings in Teva Pharmaceutical Industries by 2.6% during the fourth quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company's stock valued at $599,320,000 after acquiring an additional 688,862 shares during the period. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in Teva Pharmaceutical Industries by 2.2% in the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company's stock valued at $573,822,000 after purchasing an additional 569,412 shares during the period. Finally, Geode Capital Management LLC raised its holdings in Teva Pharmaceutical Industries by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 9,281,052 shares of the company's stock valued at $203,642,000 after acquiring an additional 489,041 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently commented on TEVA. Bank of America reduced their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. StockNews.com cut shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Monday. UBS Group reduced their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday, January 30th. Piper Sandler upped their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, January 17th. Finally, Barclays lowered their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $23.43.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock traded up $0.22 during mid-day trading on Thursday, hitting $13.65. 3,485,891 shares of the company traded hands, compared to its average volume of 9,866,926. The stock has a market cap of $15.47 billion, a price-to-earnings ratio of -9.40, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries Limited has a one year low of $12.47 and a one year high of $22.80. The stock has a fifty day moving average price of $15.57 and a 200-day moving average price of $17.73.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, equities analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.